Name |
Human Leukocyte B27 |
Alternative name/Profile |
HLA-B27, HLA B27, HLA B-27, HLAB27, Ankylosing Spondylitis, Uveitis, Juvenile Rheumatoid Arthritis |
Department |
Immunology |
Investigation |
Flow Cytometry (BD FACSCanto II) |
Specimen type |
Blood |
Sample type |
EDTA (Blood) |
Sample container & volume |
4ml Purple EDTA |
Frequency of analysis |
Weekly |
Turnaround time |
2 weeks |
Availability |
Daily, Monday to Friday |
Notes |
Useful for:
- Investigating patients with Ankylosing Spondylitis, Juvenile Rheumatoid Arthritis, Uveitis and Retier Syndrome.
Clinical Information:
- Approximately 8% of the normal population express the HLA-B27 antigen.
- Patients with rheumatic diseases such as Ankylosing Spondylitis, Juvenile Rheumatoid Arthritis, Uveitis and Reiter Syndrome have a higher prevalence of expression of HLA-B27.
- Although there is a higher prevalence of expression of HLA-B27 in patients with rheumatic disorders, the mechanism of disease association is unknown.
Please Note:
- Equivocal results for Human Leukocyte B27 (HLA-B27) will be sent to the Transplantation Laboratory, Manchester Royal Infirmary for confirmation. Consequently the turnaround time for equivocal results is approximately 8 weeks.
- Where External Institutions cannot guarantee immediate delivery, samples must be stored at room temperature and transported to St. James's Hospital within 24 hours.
|
Related links |
|
Reference range |
Negative
Positive |
Last updated |
Wed, 16 Jan 2019 16:18:50 GMT |